美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Nexentis Technologies Inc

5.81

-7.1900-55.31%

盤後：6.340.5269+9.07%19:59 EDT

成交量：243.66萬

成交額：1,551.80萬

市值：424.31萬

市盈率：-0.18

高：6.90

開：6.62

低：5.42

收：13.00

52周最高：89.79

52周最低：3.38

股本：73.03萬

流通股本：42.31萬

量比：0.17

換手率：575.84%

股息：- -

股息率：- -

每股收益(TTM):-31.4682

每股收益(LYR):-34.9551

淨資產收益率：-119.61%

總資產收益率：-37.56%

市淨率：0.33

市盈率(LYR):-0.17

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

Nexentis Technologies宣佈Mitocarex與Boltz達成合作，共同推進AI驅動的SLC小分子藥物發現

Nexentis Technologies旗下Mitocarex發現更多符合Mitoline規則的Slc蛋白

Nexentis Technologies子公司Mitocarex完成人類Slc轉運蛋白的全面分析

Nexentis 宣佈 Mitocarex Bio 達成關鍵研發里程碑，在邁向臨床前開發的道路上生成顯著優化的先導化合物

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NXTS"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NXTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXTS\",,,,,undefined,":{"symbol":"NXTS","market":"US","secType":"STK","nameCN":"Nexentis Technologies Inc","latestPrice":5.81,"timestamp":1782244800000,"preClose":13,"halted":0,"volume":2436588,"hourTrading":{"tag":"盘后","latestPrice":6.3369,"preClose":5.81,"latestTime":"19:59 EDT","volume":412398,"amount":2657954.9191,"timestamp":1782259199226,"change":0.5269,"changeRate":0.090688,"amplitude":0.216867},"delay":0,"changeRate":-0.5530769230769231,"floatShares":423136,"shares":730309,"eps":-31.468225,"marketStatus":"已收盤","change":-7.19,"latestTime":"06-23 16:00:00 EDT","open":6.62,"high":6.9,"low":5.42,"amount":15517963.783475999,"amplitude":0.113846,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-31.468225,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1782288000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":13,"preHourTrading":{"tag":"盘前","latestPrice":6.63,"preClose":13,"latestTime":"09:29 EDT","volume":291830,"amount":1965769.681568,"timestamp":1782221399999,"change":-6.37,"changeRate":-0.49,"amplitude":0.138462},"postHourTrading":{"tag":"盘后","latestPrice":6.3369,"preClose":5.81,"latestTime":"19:59 EDT","volume":412398,"amount":2657954.9191,"timestamp":1782259199226,"change":0.5269,"changeRate":0.090688,"amplitude":0.216867},"volumeRatio":0.166112},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXTS\",,,,,undefined,":{"symbol":"NXTS","floatShares":423136,"roa":"-37.56%","roe":"-119.61%","lyrEps":-34.955117,"volumeRatio":0.166112,"shares":730309,"dividePrice":0,"high":6.9,"amplitude":0.113846,"preClose":13,"low":5.42,"week52Low":3.38,"pbRate":"0.33","psRate":"20.30","week52High":89.7925,"institutionHeld":0,"latestPrice":5.81,"eps":-31.468225,"divideRate":0,"volume":2436588,"delay":0,"ttmEps":-31.468225,"open":6.62,"prevYearClose":11.76,"prevWeekClose":5.08,"prevMonthClose":5.58,"prevQuarterClose":4.62,"fiveDayClose":5.54,"twentyDayClose":4.48,"sixtyDayClose":4.7362},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NXTS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"NXTS","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-12.1},{"market":"US","date":"2026-04-08","symbol":"NXTS","defaultRemindTime":1775655000000,"type":"split","dateTimestamp":1775620800000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2026-03-31","symbol":"NXTS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774987200000,"name":null,"time":"盤後","dateTimestamp":1774929600000,"actualEps":null},{"market":"US","date":"2025-11-13","symbol":"NXTS","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-8.29},{"market":"US","date":"2025-09-22","symbol":"NXTS","defaultRemindTime":1758547800000,"type":"split","dateTimestamp":1758513600000,"forFactor":35,"toFactor":1,"ratio":35}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NXTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NXTS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NXTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NXTS","date":"2026-06-22","current":-0.199223,"percent":0.538462,"low":-1.066842,"twenty":-0.843261,"median":-0.401991,"eighty":-0.346058,"high":-0.263889,"avg":-0.526564,"sd":0.230497,"marketCap":3709385},"quantilePoints":[{"date":"2026-02-27","current":-0.435167,"twenty":-0.435167,"median":-0.435167,"eighty":-0.435167,"marketCap":2892119},{"date":"2026-03-06","current":-0.397016,"twenty":-0.415225,"median":-0.395474,"eighty":-0.392918,"marketCap":2638567},{"date":"2026-03-13","current":-0.363639,"twenty":-0.415225,"median":-0.392918,"eighty":-0.384468,"marketCap":2416744},{"date":"2026-03-20","current":-0.308842,"twenty":-0.397016,"median":-0.38658,"eighty":-0.344965,"marketCap":2052562},{"date":"2026-03-27","current":-0.285858,"twenty":-0.393932,"median":-0.363723,"eighty":-0.300138,"marketCap":1899813},{"date":"2026-04-02","current":-0.277831,"twenty":-0.393121,"median":-0.344965,"eighty":-0.278879,"marketCap":1846463},{"date":"2026-04-10","current":-0.848002,"twenty":-0.4161,"median":-0.367697,"eighty":-0.282571,"marketCap":3395402},{"date":"2026-04-17","current":-0.723994,"twenty":-0.439299,"median":-0.384468,"eighty":-0.285385,"marketCap":2898870},{"date":"2026-04-24","current":-0.913654,"twenty":-0.754631,"median":-0.392896,"eighty":-0.297282,"marketCap":3658271},{"date":"2026-05-01","current":-0.869886,"twenty":-0.840693,"median":-0.397016,"eighty":-0.307101,"marketCap":3483025},{"date":"2026-05-08","current":-1.066842,"twenty":-0.847273,"median":-0.423688,"eighty":-0.318981,"marketCap":4271634},{"date":"2026-05-15","current":-0.846179,"twenty":-0.852197,"median":-0.435167,"eighty":-0.327296,"marketCap":3388100},{"date":"2026-05-22","current":-0.343676,"twenty":-0.848732,"median":-0.423688,"eighty":-0.328308,"marketCap":3227457},{"date":"2026-05-29","current":-0.389551,"twenty":-0.847455,"median":-0.408608,"eighty":-0.337702,"marketCap":3658271},{"date":"2026-06-05","current":-0.393439,"twenty":-0.846544,"median":-0.402769,"eighty":-0.343909,"marketCap":3694781},{"date":"2026-06-12","current":-0.389551,"twenty":-0.845085,"median":-0.400825,"eighty":-0.344605,"marketCap":3658271},{"date":"2026-06-18","current":-0.41521,"twenty":-0.843625,"median":-0.40238,"eighty":-0.345693,"marketCap":3899235},{"date":"2026-06-22","current":-0.394994,"twenty":-0.843261,"median":-0.401991,"eighty":-0.346058,"marketCap":3709385}],"updateTime":1782224921482},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NXTS\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1158947150","title":"Nexentis Technologies宣佈Mitocarex與Boltz達成合作，共同推進AI驅動的SLC小分子藥物發現","url":"https://stock-news.laohu8.com/highlight/detail?id=1158947150","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158947150?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 20:24","pubTimestamp":1782131058,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc宣布，其旗下Mitocarex部门已与Boltz公司达成合作，将共同利用人工智能技术推进SLC（溶质载体）小分子药物的发现工作。此次合作旨在结合双方在生物技术与人工智能算法领域的专长，加速针对SLC靶点的新药研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130882652","title":"Nexentis Technologies旗下Mitocarex發現更多符合Mitoline規則的Slc蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=1130882652","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130882652?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 19:34","pubTimestamp":1781696067,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc. 宣布，其旗下公司Mitocarex在研究中取得新进展，识别出了更多符合“Mitoline”规则集的溶质载体蛋白。这一发现有望为基于该技术平台的新药研发提供更广阔的目标选择空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NXTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119676886","title":"Nexentis Technologies子公司Mitocarex完成人類Slc轉運蛋白的全面分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1119676886","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119676886?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 19:33","pubTimestamp":1781695994,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc的子公司Mitocarex宣布，已完成对人类溶质载体（Slc）转运蛋白家族的全面分析。这项研究旨在深入探索该蛋白家族在细胞代谢和药物转运中的关键作用，为后续的药物靶点发现和新型疗法开发奠定重要的科学基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171654842","title":"Nexentis 宣佈 Mitocarex Bio 達成關鍵研發里程碑，在邁向臨床前開發的道路上生成顯著優化的先導化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1171654842","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171654842?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 21:33","pubTimestamp":1779111196,"startTime":"0","endTime":"0","summary":"Nexentis Technologies Inc 近日宣布，其旗下的Mitocarex Bio项目已成功达成一项关键的研发里程碑。该项目在通往临床前开发的道路上取得了重要进展，成功生成了一种经过显著优化的先导化合物分子。这一突破标志着该候选药物在早期开发阶段迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTS","BK4093"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NXTS\",params:#limit:6,delay:false,,,undefined,":[]}}